Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients.
2022-01-01 Conteduca, V; Scarpi, E; Wetterskog, D; Brighi, N; Ferroni, F; Rossi, A; Romanel, A; Gurioli, G; Bleve, S; Gianni, C; Schepisi, G; Lolli, C; Cortesi, P; Matteucci, F; Barone, D; Paganelli, G; Demichelis, F; Beltran, H; Attard, G; De Giorgi, U.
Plasma Androgen Receptor in Prostate Cancer.
2019-01-01 Conteduca, V; Gurioli, G; Brighi, N; Lolli, C; Schepisi, G; Casadei, C; Burgio, Sl; Gargiulo, S; Ravaglia, G; Rossi, L; Altavilla, A; Farolfi, A; Menna, C; Colangione, Sp; Pulvirenti, M; Romeo, A; De Giorgi, U.
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
2021-01-01 Conteduca, V; Wetterskog, D; Castro, E; Scarpi, E; Romero-Laorden, N; Gurioli, G; Jayaram, A; Lolli, C; Schepisi, G; Wingate, A; Casadei, C; Lozano, R; Brighi, N; Aragón, Im; Marin-Aguilera, M; Gonzalez-Billalabeitia, E; Mellado, B; Olmos, D; Attard, G; De Giorgi, U.
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis.
2019-01-01 Jayaram, A; Wingate, A; Wetterskog, D; Conteduca, V; Khalaf, D; Sharabiani, Mta; Calabrò, F; Barwell, L; Feyerabend, S; Grande, E; Martinez-Carrasco, A; Font, A; Berruti, A; Sternberg, Cn; Jones, R; Lefresne, F; Lahaye, M; Thomas, S; Joshi, S; Shen, D; Ricci, D; Gormley, M; Merseburger, As; Tombal, B; Annala, M; Chi, Kn; De Giorgi, U; Gonzalez-Billalabeitia, E; Wyatt, Aw; Attard, G.
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide.
2020-01-01 Gurioli, G; Conteduca, V; Lolli, C; Schepisi, G; Gargiulo, S; Altavilla, A; Casadei, C; Scarpi, E; De Giorgi, U.
Urinary RNA-based biomarkers for prostate cancer detection
2017-01-01 Martignano, F.; Rossi, L.; Maugeri, A.; Galla, V.; Conteduca, V.; De Giorgi, U.; Casadio, V.; Schepisi, G.
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724–31
2016-01-01 Conteduca, V.; Lolli, C.; De Giorgi, U.
B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia
2013-01-01 Sansonno, D.; Russi, S.; Conteduca, V.; Sansonno, L.
Hepatitis C virus infection and mixed cryoglobulinemia
2012-01-01 Lauletta, G.; Russi, S.; Conteduca, V.; Sansonno, L.
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients
2015-01-01 Conteduca, V.; Caffo, O.; Fratino, L.; Lo Re, G.; Basso, U.; D'Angelo, A.; Donini, M.; Verderame, F.; Ratta, R.; Procopio, G.; Campadelli, E.; Massari, F.; Gasparro, D.; Ermacora, P.; Messina, C.; Giordano, M.; Alesini, D.; Zagonel, V.; Veccia, A.; Lolli, C.; Maines, F.; De Giorgi, U.
Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
2018-01-01 Caroli, P.; De Giorgi, U.; Scarpi, E.; Fantini, L.; Moretti, A.; Galassi, R.; Celli, M.; Conteduca, V.; Rossi, L.; Bianchi, E.; Paganelli, G.; Matteucci, F.
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
2016-01-01 Lolli, C.; Basso, U.; Derosa, L.; Scarpi, E.; Sava, T.; Santoni, M.; Crabb, S. J.; Massari, F.; Aieta, M.; Conteduca, V.; Maruzzo, M.; La Russa, F.; Wheater, M.; Berardi, R.; Galli, L.; De Giorgi, U.
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone
2016-01-01 Lolli, C.; Caffo, O.; Scarpi, E.; Aieta, M.; Conteduca, V.; Maines, F.; Bianchi, E.; Massari, F.; Veccia, A.; Chiuri, V. E.; Facchini, G.; De Giorgi, U.
Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7
2018-01-01 De Giorgi, U.; Conteduca, V.; Scarpi, E.
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
2015-01-01 Salvi, S.; Casadio, V.; Conteduca, V.; Burgio, S. L.; Menna, C.; Bianchi, E.; Rossi, L.; Carretta, E.; Masini, C.; Amadori, D.; Calistri, D.; Attard, G.; De Giorgi, U.
CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone
2016-01-01 Salvi, S.; Casadio, V.; Burgio, S. L.; Conteduca, V.; Rossi, L.; Menna, C.; Carretta, E.; Costantini, M.; Zoli, W.; De Giorgi, U.
The emerging role of anti-angiogenic therapy in ovarian cancer (review)
2014-01-01 Conteduca, V.; Kopf, B.; Burgio, S. L.; Bianchi, E.; Amadori, D.; De Giorgi, U.
Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis
2008-01-01 Sansonno, D.; Tucci, F. A.; Troiani, L.; Lauletta, G.; Montrone, M.; Conteduca, V.; Sansonno, L.; Dammacco, F.
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
2013-01-01 Tartarone, A.; Lazzari, C.; Lerose, R.; Conteduca, V.; Improta, G.; Zupa, A.; Bulotta, A.; Aieta, M.; Gregorc, V.
Pivotal Trials in Multiple Sclerosis: Similarities Prove Not to Be Useful
2022-01-01 Avolio, Carlo; Centonze, Diego
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. | 1-gen-2022 | Conteduca, V; Scarpi, E; Wetterskog, D; Brighi, N; Ferroni, F; Rossi, A; Romanel, A; Gurioli, G; Bleve, S; Gianni, C; Schepisi, G; Lolli, C; Cortesi, P; Matteucci, F; Barone, D; Paganelli, G; Demichelis, F; Beltran, H; Attard, G; De Giorgi, U. | |
| Plasma Androgen Receptor in Prostate Cancer. | 1-gen-2019 | Conteduca, V; Gurioli, G; Brighi, N; Lolli, C; Schepisi, G; Casadei, C; Burgio, Sl; Gargiulo, S; Ravaglia, G; Rossi, L; Altavilla, A; Farolfi, A; Menna, C; Colangione, Sp; Pulvirenti, M; Romeo, A; De Giorgi, U. | |
| Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. | 1-gen-2021 | Conteduca, V; Wetterskog, D; Castro, E; Scarpi, E; Romero-Laorden, N; Gurioli, G; Jayaram, A; Lolli, C; Schepisi, G; Wingate, A; Casadei, C; Lozano, R; Brighi, N; Aragón, Im; Marin-Aguilera, M; Gonzalez-Billalabeitia, E; Mellado, B; Olmos, D; Attard, G; De Giorgi, U. | |
| Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. | 1-gen-2019 | Jayaram, A; Wingate, A; Wetterskog, D; Conteduca, V; Khalaf, D; Sharabiani, Mta; Calabrò, F; Barwell, L; Feyerabend, S; Grande, E; Martinez-Carrasco, A; Font, A; Berruti, A; Sternberg, Cn; Jones, R; Lefresne, F; Lahaye, M; Thomas, S; Joshi, S; Shen, D; Ricci, D; Gormley, M; Merseburger, As; Tombal, B; Annala, M; Chi, Kn; De Giorgi, U; Gonzalez-Billalabeitia, E; Wyatt, Aw; Attard, G. | |
| Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide. | 1-gen-2020 | Gurioli, G; Conteduca, V; Lolli, C; Schepisi, G; Gargiulo, S; Altavilla, A; Casadei, C; Scarpi, E; De Giorgi, U. | |
| Urinary RNA-based biomarkers for prostate cancer detection | 1-gen-2017 | Martignano, F.; Rossi, L.; Maugeri, A.; Galla, V.; Conteduca, V.; De Giorgi, U.; Casadio, V.; Schepisi, G. | |
| Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724–31 | 1-gen-2016 | Conteduca, V.; Lolli, C.; De Giorgi, U. | |
| B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia | 1-gen-2013 | Sansonno, D.; Russi, S.; Conteduca, V.; Sansonno, L. | |
| Hepatitis C virus infection and mixed cryoglobulinemia | 1-gen-2012 | Lauletta, G.; Russi, S.; Conteduca, V.; Sansonno, L. | |
| Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients | 1-gen-2015 | Conteduca, V.; Caffo, O.; Fratino, L.; Lo Re, G.; Basso, U.; D'Angelo, A.; Donini, M.; Verderame, F.; Ratta, R.; Procopio, G.; Campadelli, E.; Massari, F.; Gasparro, D.; Ermacora, P.; Messina, C.; Giordano, M.; Alesini, D.; Zagonel, V.; Veccia, A.; Lolli, C.; Maines, F.; De Giorgi, U. | |
| Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide | 1-gen-2018 | Caroli, P.; De Giorgi, U.; Scarpi, E.; Fantini, L.; Moretti, A.; Galassi, R.; Celli, M.; Conteduca, V.; Rossi, L.; Bianchi, E.; Paganelli, G.; Matteucci, F. | |
| Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib | 1-gen-2016 | Lolli, C.; Basso, U.; Derosa, L.; Scarpi, E.; Sava, T.; Santoni, M.; Crabb, S. J.; Massari, F.; Aieta, M.; Conteduca, V.; Maruzzo, M.; La Russa, F.; Wheater, M.; Berardi, R.; Galli, L.; De Giorgi, U. | |
| Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone | 1-gen-2016 | Lolli, C.; Caffo, O.; Scarpi, E.; Aieta, M.; Conteduca, V.; Maines, F.; Bianchi, E.; Massari, F.; Veccia, A.; Chiuri, V. E.; Facchini, G.; De Giorgi, U. | |
| Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 | 1-gen-2018 | De Giorgi, U.; Conteduca, V.; Scarpi, E. | |
| Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone | 1-gen-2015 | Salvi, S.; Casadio, V.; Conteduca, V.; Burgio, S. L.; Menna, C.; Bianchi, E.; Rossi, L.; Carretta, E.; Masini, C.; Amadori, D.; Calistri, D.; Attard, G.; De Giorgi, U. | |
| CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone | 1-gen-2016 | Salvi, S.; Casadio, V.; Burgio, S. L.; Conteduca, V.; Rossi, L.; Menna, C.; Carretta, E.; Costantini, M.; Zoli, W.; De Giorgi, U. | |
| The emerging role of anti-angiogenic therapy in ovarian cancer (review) | 1-gen-2014 | Conteduca, V.; Kopf, B.; Burgio, S. L.; Bianchi, E.; Amadori, D.; De Giorgi, U. | |
| Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis | 1-gen-2008 | Sansonno, D.; Tucci, F. A.; Troiani, L.; Lauletta, G.; Montrone, M.; Conteduca, V.; Sansonno, L.; Dammacco, F. | |
| Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib | 1-gen-2013 | Tartarone, A.; Lazzari, C.; Lerose, R.; Conteduca, V.; Improta, G.; Zupa, A.; Bulotta, A.; Aieta, M.; Gregorc, V. | |
| Pivotal Trials in Multiple Sclerosis: Similarities Prove Not to Be Useful | 1-gen-2022 | Avolio, Carlo; Centonze, Diego |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista31120
- 4 Contributo in Atti di Convegno ...3
Data di pubblicazione
- In corso di stampa39
- 2020 - 20269083
- 2010 - 201911275
- 2000 - 20096752
- 1990 - 19992845
- 1980 - 1989901
- 1970 - 1979224
- 1967 - 19693
Editore
- Lippincott, Williams & Wilkins:53...116
- Giuffre Editore Spa:via Busto Ars...112
- Elsevier Science Limited:Oxford F...106
- Elsevier BV:PO Box 211, 1000 AE A...103
- Blackwell Munksgaard:PO Box 2148,...93
- Blackwell Science Limited:PO Box ...91
- Edizioni Minerva Medica:Corso Bra...74
- Chiriotti Editori Spa:PO Box 66, ...70
- W B Saunders Company:Fulfillment ...69
- Springer Verlag Germany:Tiergarte...65
Rivista
- PHYSICAL REVIEW LETTERS267
- PHYSICS LETTERS. SECTION B182
- JOURNAL OF CLINICAL MEDICINE169
- INTERNATIONAL JOURNAL OF MOLECULA...166
- PHYSICAL REVIEW D, PARTICLES, FIE...161
- ACTA HORTICULTURAE159
- INTERNATIONAL JOURNAL OF CARDIOLOGY145
- PLOS ONE138
- JOURNAL OF BIOLOGICAL REGULATORS ...127
- LA RADIOLOGIA MEDICA126
Keyword
- Humans1202
- Male648
- Female591
- Middle Aged399
- Adult327
- Aged325
- Italy285
- COVID-19246
- Animals221
- Medicine (all)160
Lingua
- eng18061
- ita5528
- spa132
- fre99
- ger44
- lat30
- grc27
- enm19
- por18
- pol5
Accesso al fulltext
- no fulltext30652
- open363
- restricted77
- reserved29
- partially open1